The FDA granted approval to Guardant Health’s Guardant360 assay as a companion diagnostic to support Eli Lilly’s Inluriyo breast cancer drug. This marks the sixth companion diagnostic cleared for Guardant360, part of the company’s efforts to enable personalized cancer treatment through comprehensive genomic profiling. The test is designed to assist oncologists in matching patients with targeted therapies, enhancing clinical decision-making in breast cancer management.